Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques

Sofra, Maria; Antenucci, Anna; Gallucci, Michele; Mandoj, Chiara; Papalia, Rocco; Claroni, Claudia; Monteferrante, Ilaria; Torregiani, Giulia; Gianaroli, Valeria; Sperduti, Isabella; Tomao, Luigi; Forastiere, Ester

doi:10.1186/s13046-014-0063-z

Cited by 5 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our extensive literature search initially resulted in 1835 articles. Rigorous examination for duplication, accessibility of full texts, and adherence to our predefined inclusion criteria led to the selection of 9 studies 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 for our meta‐analysis, as detailed in Figure 1 . The characteristics and interventions of these studies, encompassing a total of 2063 patients undergoing robotic surgery for prostate cancer, are comprehensively described in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

A meta‐analysis of postoperative wound complications at the surgical site in prostate cancer patients undergoing robotic surgery

Su,

Dai,

Zhao

et al. 2023

International Wound Journal

View full text Add to dashboard Cite

This meta‐analysis critically evaluates the role of robotic surgery in reducing postoperative wound complications in prostate cancer patients, comparing it with traditional open and laparoscopic approaches. Our extensive literature search resulted in 9 studies comprising 2063 patients. The results highlighted a significant reduction in the incidence of wound complications, with an 84% heterogeneity index and a standardized mean difference (SMD) of 0.49 (95% Confidence Intervals: 0.42 to 0.58, p < 0.01) in favour of robotic surgery. Additionally, a notable decrease in wound infection rates was observed, marked by a 94% heterogeneity index and a SMD of 0.26 (95% CIs: 0.19 to 0.35, p < 0.01). A considerable reduction in wound dehiscence events was also noted, particularly in a subset of studies, reflecting a 70% heterogeneity index and a SMD of 0.23 (95% CIs: 0.12 to 0.45, p < 0.01). These findings suggest that robotic surgery may offer significant advantages in managing wound‐related outcomes in prostate cancer surgeries. However, the variability among the studies warrants cautious interpretation of the results and underscores the need for more targeted research in this area.

show abstract

Section: Resultsmentioning

confidence: 99%

A meta‐analysis of postoperative wound complications at the surgical site in prostate cancer patients undergoing robotic surgery

Su,

Dai,

Zhao

et al. 2023

International Wound Journal

View full text Add to dashboard Cite

show abstract

PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience

Merola

Tomao

Antenucci

et al. 2015

J Exp Clin Cancer Res

Self Cite

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is the most common male cancer in Europe and the US. The early diagnosis relies on prostate specific antigen (PSA) serum test, even if it showed clear limits. Among the new tests currently under study, one of the most promising is the prostate cancer gene 3 (PCA3), a non-coding mRNA whose level increases up to 100 times in PCa tissues when compared to normal tissues. With the present study we contribute to the validation of the clinical utility of the PCA3 test and to the evaluation of its prognostic potential.Methods407 Italian men, with two or more PCa risk factors and at least a previous negative biopsy, entering the Urology Unit of Regina Elena National Cancer Institute, were tested for PCA3, total PSA (tPSA) and free PSA (fPSA and f/tPSA) tests. Out of the 407 men enrolled, 195 were positive for PCa and 114 of them received an accurate staging with evaluation of the Gleason score (Gs). Then, the PCA3 score was correlated to biopsy outcome, and the diagnostic and prognostic utility were evaluated.ResultsOut of the 407 biopsies performed after the PCA3 test, 195 (48%) resulted positive for PCa; the PCA3 score was significantly higher in this population (p < 0.0001) differently to tPSA (p = 0.87). Moreover, the PCA3 test outperformed the f/tPSA (p = 0.01). The sensitivity (94.9) and specificity (60.1) of the PCA3 test showed a better balance for a threshold of 35 when compared to 20, even if the best result was achieved considering a cutoff of 51, with sensitivity and specificity of 82.1% and 79.3%, respectively. Finally, comparing values of the PCA3 test between two subgroups with increasing Gs (Gs ≤ 6 versus Gs ≥ 7) a significant association between PCA3 score and Gs was found (p = 0.02).ConclusionsThe PCA3 test showed the best diagnostic performance when compared to tPSA and f/tPSA, facilitating the selection of high-risk patients that may benefit from the execution of a saturation prostatic biopsy. Moreover, the PCA3 test showed a prognostic value, as higher PCA3 score values are associated to a greater tumor aggressiveness.

show abstract

MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma

Guo

Wang

Liu

2015

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Elucidation of the downstream targets regulated by the metastasis-suppressive miRNAs can shed light on the metastatic processes in prostate cancer (PCa). We conducted microarray analyses and found that miR-195 was significantly decreased in metastatic PCa. Low miR-195 expression is an independent prognostic factor for poor biochemical recurrence-free and overall survival. Forced expression of miR-195 in PCa cells drastically inhibits proliferation, migration and invasion in vitro and inhibits tumor growth and metastasis in vivo. BCOX1 is identified as a direct target of miR-195 in PCa, and is found to be drastically increased in metastatic PCa. BCOX1 knockdown phenotypically copies miR-195-induced phenotypes, whereas forced expression of BCOX1 reverses the effects of miR-195. Collectively, this is the first report unveils that loss of miR-195 expression and thus uncontrolled BCOX1 upregulation might drive PCa metastasis.Electronic supplementary materialThe online version of this article (doi:10.1186/s13046-015-0209-7) contains supplementary material, which is available to authorized users.

show abstract

Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques

Cited by 5 publications

References 47 publications

A meta‐analysis of postoperative wound complications at the surgical site in prostate cancer patients undergoing robotic surgery

A meta‐analysis of postoperative wound complications at the surgical site in prostate cancer patients undergoing robotic surgery

PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience

MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma

Contact Info

Product

Resources

About